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Abstract
Traumatic brain injury has a devastating effect on millions worldwide each year. As yet, there are no methods which have
been proven to improve recovery from the trauma. Current treatment protocols revolve around reducing secondary
insult, such as hypoxia, hypotension, and cerebral edema, which raises intracranial pressure. The purpose of this study is
to assess the efficacy of three responses to traumatic brain injury. Two of them, the administration of hypertonic saline
and the administration of progesterone, are pharmacologic, while the third, the performance of a decompressive craniectomy, is surgically invasive. A number of original studies have been analyzed to develop an understanding of the topic. It
was concluded that hypertonic saline should only be given to patients in whom surgery is indicated, while progesterone
should be a widespread acute response. For relatively young patients suffering from uncontrollable intracranial pressure,
decompressive craniectomy should be considered as an immediate response as well.
Introduction
Traumatic brain injury serves as a major cause of death and
disability. Over one million people are treated for traumatic
brain injury in emergency rooms in America each year. Fifty
thousand die as a result, while seventy to ninety thousand are
left with debilitating long term neurological impairment. Among
men under the age of 35, traumatic brain injury as a result of
vehicular accident is the leading cause of death and disability
(Shear, et al. 2002). Besides for the direct effects of the primary
injury, outcomes are affected by the onset of secondary insult.
Such insult includes the onset of hypoxia, hypotension, and an
increase in intracranial pressure, which is often due to cranial
edema. Hypotension has been correlated with a mortality rate
which is double that of patients without the condition (Cooper,
et al. 2004; Cooper, et al. 2012; Shackford, et al. 1998). As yet, no
pharmacologic agent has been proven to improve the outcome
of traumatic brain injury, notwithstanding the intense efforts of
many researchers. To date, the management of traumatic brain
injury consists of preventing further neurologic insults, managing intracranial pressure, and instituting surgical procedures to
minimize damage (Shear, et al. 2002; Wright, et al. 2007; Xiao, et
al. 2008).
The severity of a traumatic brain injury is universally measured
according to the Glasgow Coma Scale, which assesses eye, verbal and motor condition following the injury. The scale which is
most often used is the Extended Glasgow Coma Scale, which
ranges from 3 to 15, awarding points for various functions which
can be achieved. A score on the Glasgow Coma Scale of 3 indicates death or a deep coma, while a 15 indicates complete
consciousness.
The outcome of traumatic brain injury is universally assessed
according to the Extended Glasgow Outcome Scale, which is
highly sensitive. It consists of eight diagnoses, which are: Dead,
Vegetative State, Lower Severe Disability, Upper Severe Disability,
Lower Moderate Disability, Upper Moderate Disability, Lower
Good Recovery, and Upper Good Recovery This study aims to
analyze and assess the effectiveness of three of the current acute
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responses to traumatic brain injury, including both chemical and
surgical options. Methods used to decrease intracranial pressure
include hypertonic saline resuscitation and the administration of
progesterone, which has been touted as a neuroprotector. The
performance of decompressive craniectomy has also been factored into this study.

Hypertonic Saline
Hypertonic saline is administered intravenously, often en route
to the hospital. The underlying claim to the administration of
hypertonic saline is that it restores systemic blood pressure
and cardiac output to manageable levels with less volume being
necessary than when using the standard Lactated Ringer’s solution. The hypertonic saline extracts water from the intracellular
space in order to restore intravascular losses and it has a positive
inotropic effect on cardiac output. In addition, hypertonic saline
has been shown to improve oxygen transport, mesenteric and
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coronary blood flow, myocardial contractility, and redistribution of extracellular and interstitial fluid (Mattox, et al. 1991;
Shackford, et al. 1998).

hypertonic saline, as compared to a positive trend in the intracranial pressure of patients receiving Lactated Ringer’s solution.
This data was observed on the second day following trauma
(Shackford, et al. 1998).

Progesterone
Progesterone is administered in a similar fashion to hypertonic
saline. The concept of using progesterone to alleviate problems
caused by traumatic brain injury was discovered when researchers noticed a significant sex difference in trauma outcome in
correlation to hormonal cycling. Female rats with elevated
levels of progesterone showed reduced tissue damage and improved behavioral recovery (Shear, et al. 2002). As progesterone
has been used safely on humans for years, it was hoped that
it would have a positive effect on people with traumatic brain
injury (Wright, et al. 2007).While the mechanism is unknown as
of yet, progesterone has been shown to reduce cerebral edema,
prevent neuronal loss, improve functional outcome, and inhibit
oxidative damage in the central nervous system. It might also
promote peripheral remyelination of axons following injury.
Progesterone is lipid soluble, so it rapidly crosses the bloodbrain barrier to reach equilibrium within an hour of administration (Shear, et al. 2002; Wright, et al. 2007; Xiao, et al. 2008).

Decompressive Craniectom
Decompressive craniectomy is a surgical measure which is taken
when patients present with dangerously high intracranial pressure. Part of the skull is removed to allow room for the brain
to swell. Proponents of decompressive craniectomy state that it
can relieve uncontrollable intracranial pressure by increasing the
volumetric capacity of the intracranial cavity. Craniectomies have
been performed since the early nineteenth century, with varying
degrees of success (Akyuz, et al. 2010; Morgalla, et al. 2008).

Methods
This study was performed through analyzation of published original studies on the effects of hypertonic saline, progesterone, and
decompressive craniectomy on traumatic brain injury. Sources
include TouroLib databases, PubMed databases, and the archives
of Lancet.

Discussion
Hypertonic saline was found in all cases to be safe for use.
Shackford, et al. (1998) do caution that solutions that are too
hypertonic are liable to reversibly open the blood-brain barrier, cause cerebral edema, and increase intracranial pressure.
However, great care is taken to assure that proper proportions
are used. Solutions that are 7.5% hypertonic saline have been
shown to be both safe and effective (Bulger, et al. 2010; Cooper,
et al. 2004; Mattox, et al. 1991). Administration of hypertonic saline causes a slight increase in intracranial compliance, as shown
by a decrease in mean intracranial pressure in patients receiving

When administering hypertonic saline, fluid input must be
increased, as the saline decreases the fluid balance. No cases
of renal failure or neurological complications due to hypernatremia or hyperosmolarity have been found, but precautions
should be taken all the same (Shackford, et al. 1998).
Patients receiving hypertonic saline showed a higher rate of nosocomial infection due to the increased rate of the bloodstream.
The increased amount of fluid output also led to a higher incidence of urinary tract infections. In addition, administration
of hypertonic saline might cause regulation of the A3 receptor
on neutrophils, which would cause an increase in susceptibility
to infection (Bulger, et al. 2010). Patients receiving hypertonic
saline required a greater number of interventions to lower intracranial pressure over the course of their hospitalization, but
the difference was not significant (Shackford, et al. 1998).
While many studies have attempted to prove the superiority of
hypertonic saline over other standard protocols, such as mannitol and Lactated Ringer’s solution, most have been unsuccessful.
Out of five studies analyzed, only one study conclusively stated
that hypertonic saline was universally preferable to mannitol. In
that study, Battison, et al. (2005) administered four doses each
to nine patients. Two doses were of hypertonic saline and two
were of mannitol, in no particular order. The minimum intracranial pressure was measured ten minutes before each treatment
and was compared with the minimum intracranial pressure an
hour after each treatment. While hypertonic saline reduced
the intracranial pressure slightly more than mannitol did, there
was no significant difference. The duration of the effect, however, was seen to be significantly longer in hypertonic saline.
This study cannot be seen as conclusive, though, as it was only
done on nine patients. In addition, the patients received both
mannitol and hypertonic saline over a set period of time. As
such, the effect could be due to the presence of both mannitol
and hypertonic saline in their systems, and cannot be attributed
solely to the hypertonic saline.
Hypertonic saline has been shown to work slightly faster than
controls. Cooper reports that patients receiving hypertonic saline had a faster rate of decrease in intracranial pressure than
those in the control group. However, the study also states that
standard protocols are equally effective. All studies concur that
there is no significant difference in favorable outcomes of patients who receive hypertonic saline and those who are treated
with standard measures (Battison, et al. 2005; Bulger, et al. 2010;
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Cooper, et al. 2004; Mattox, et al. 1991; Shackford, et al. 1998).
While it may improve physiologic parameters, the long term
benefit of administering hypertonic saline is negligible. Patients
who received 7.5% hypertonic saline and those who received
Lactated Ringer’s solution showed identical neurologic function
after six months. The percentage of patients who survived to
hospital discharge was similar. Studies found no significant difference in intracranial pressure for the duration of hospital stay,
and there was no discernible difference in Glasgow Outcome
Scale values. (Bulger, et al. 2010; Cooper, et al. 2004; Mattox, et
al. 1991; Shackford, et al. 1998).

was noted, as well as an increase in peripheral remyelination of
axons, an inhibition of oxidative damage in the central nervous
system, and an overall enhanced recovery from cortical, cerebral, and spinal cord injury (Pan, et al. 2007; Shear, et al. 2002;
Wright, et al. 2007; Xiao, et al. 2008).

Progesterone

There has been much speculation as to the mechanism behind
progesterone. It has been ascertained that it works, but not how
it works. Progesterone down-regulates the inflammatory cytokine cascade, which can increase the damage caused by trauma.
Trauma causes a release of amino acids, which cause neuronal
exitotoxicity. Progesterone might act at the GABA receptor to
diminish that exitotoxicity (Shear, et al. 2002). The study by Pan,
et al. (2007) posits that progesterone acts as a sigma-1 receptor
antagonist, which can initiate the opioid-like capabilities of the
receptor. In addition, progesterone inhibits nuclear factor kappa
B, which is known to be a pro-inflammatory transcription factor.
Nuclear factor kappa B is the activator of numerous inflammatory cytokines, including tumor necrosis factor alpha, interleukin-1 beta, C3, and glial fibrillary acidic protein. Thus, inhibition
of nuclear factor kappa B decreases system-wide inflammation
(Pan, et al. 2007).

Aside from its long history of safe use, progesterone has been
proven to be completely safe for use in humans. A study was
performed with the express purpose of determining the safety of progesterone as a response to traumatic brain injury
(Wright, et al. 2007). It was found that administration of progesterone was in no way harmful to patients, and it was indicated that it might be beneficial to their recovery. Furthermore,
endogenously released progesterone causes a 1° F increase
in core body temperature. This deviation from standard basal
temperature might hinder neurologic outcome in a patient with
traumatic brain injury. However, the study found that no such
increase in body temperature manifested in relation to administered progesterone.

The timing and duration of administration are key to the effectivity of progesterone. Most studies found a correlation
between speedy dispensation of progesterone and favorable
outcome. Wright et al. (2007) reports that the greatest benefit
is gleaned when progesterone is administered within two hours
of injury, but that there is still great advantage when it is given
within 24 hours. Pan et al. (2007) and Shear et al. (2002) both
started treatment within an hour of injury. It was noted that
there is a consistent reduction in formation of cerebral edema
when progesterone is given within 24 hours of injury (Shear,
et al. 2002). There is a consensus that much of the success of
progesterone is dependent upon the timing of its initiation.

Multiple studies have found immense short term and long term
benefits from the use of progesterone as an acute response
to traumatic brain injury. Patients receiving progesterone had
significantly fewer deaths due to neurologic causes. At 30 days
postinjury, the mortality rate of patients receiving progesterone was less than half of that of the control group (Wright,
et al. 2007). A significant difference in neurologic outcome was
evident up to six months post-treatment, with the experimental group having a 58% favorable outcome as compared to the
control’s 42% (Xiao, et al. 2008). In addition, treated patients
showed a decrease in cerebral edema, necrotic cavity formation, and neuronal loss as compared to control groups, which
presented with neuronal and glial shrinkage and neutrophil infiltration. For example, necrotic cavity formation decreased by
approximately 20% in treated patients. A decrease in apoptosis

The duration of administration is slightly more controversial.
One study, citing the contradictory effects of inflammatory cytokines, limited the duration of progesterone to 24 hours. The
researchers claimed that while immediately following an injury,
inflammatory cytokines are neurotoxic, they are later neuroprotective. Seeking to block the initial harmful effect of inflammatory
cytokines yet capitalize on their latent neuroprotective abilities,
the study administered progesterone from 30 minutes to 24
hours following injury, at which time they ceased administration
of the treatment (Pan, et al. 2007). However, other studies noted
that the greatest benefit was attained when progesterone was
administered for five days (Shear, et al. 2002; Xiao, et al. 2008). In
the experiment carried out by Shear, et al. (2002) on rodents, one
group received progesterone for three days, while the other received it for five. It was concluded that five days of progesterone

Patients who were to undergo surgery showed a far better outcome when given hypertonic saline in dextran (Mattox, et al.
1991). However, at this time, hypertonic saline in dextran is quite
expensive, as compared to the cost of standard treatments, such
as Lactated Ringer’s solution and mannitol (Battison, et al. 2005).
Therefore, rather than staying as a first tier response to traumatic brain injury, perhaps hypertonic saline should be relegated
to a measure which is used only when surgery is indicated.

52

Responses to Traumatic Brain Injury

are necessary to achieve the desired results, namely an alleviation
of the neuropathological and behavioral abnormalities which are
caused by traumatic brain injury. This finding seems to contradict
that of Pan’s. However, as harmful consequences of extending
the progesterone treatment have not been found, it might be advantageous to forfeit the possible neuroprotective capabilities of
inflammatory cytokines in favor of the documented benefits of an
extended progesterone treatment.

Decompressive Craniectomy
Craniectomy has long been used as a last resort in the treatment of traumatic brain injury. It is only when indicators of
incredibly high intracranial pressure manifest that craniectomy
is considered. Such indicators include compression of cortical
gyri and basal cisterns, signs of immediate herniation, and cerebral swelling (Morgalla, et al. 2008). In the majority of studies
analyzed, craniectomy was only used after standard protocols
had failed to lower intracranial pressure sufficiently. As such, it
is difficult to assess the efficacy of craniectomy, as it is generally
used only on patients with severe injuries who have already
undergone other treatments. Usually, by the time a craniectomy
is performed, there has been a lapse of time between injury and
the surgery (Morgalla, et al. 2008; Olivecrona, et al. 2007), limiting its benefit. Another hindrance to the study of decompressive
craniectomy is that due to the surgical nature of the procedure,
a blinded study is impossible.
While one study analyzed found decompressive craniectomy
to lower intracranial pressure but hinder favorable outcome
(Cooper, et al. 2012), four other studies found that long term
results justify the surgery (Akyuz, et al. 2010; Morgalla, et al.
2008; Olivecrona, et al. 2007; Qiu, et al. 2009). Cooper, et al.’s
2012 study reports that patients who received a craniectomy
along with standard treatment showed a less favorable outcome
after six months. However, the mortality rate was the same in
patients who had undergone the procedure and those who had
not. In contrast, Olivecrona, et al. (2007) found a 10% difference
in outcome, with those who received a decompressive craniectomy having the more favorable outcomes when compared to
patients who received only standard care.
Patients who had undergone a decompressive craniectomy
needed fewer interventions to lower intracranial pressure.They
required a shorter period of time on mechanical ventilation,
and they spent a shorter amount of time in the intensive care
unit (Cooper, et al. 2012). There was a significant reduction in
intracranial pressure directly after the surgery, which later stabilized to manageable levels (Olivecrona, et al. 2007). One study
found that 40% of patients who were otherwise likely to die had
favorable results after undergoing a decompressive craniectomy
(Morgalla, et al. 2008).

There are a number of caveats in regard to craniectomies.
Firstly, patients who underwent the surgery had a higher incidence of hydrocephalus (Cooper, et al. 2012), which necessitates additional medical or surgical care. Secondly, unilateral
craniectomies have been linked to delayed intracranial hematomas and subdural effusion, both of which must be treated
through surgical intervention (Qiu, et al. 2009). However, success has been seen in bilateral craniectomies. A problem with
all decompressive craniectomies seems to be an increase in
transcapillary leakage. The point of a craniectomy is to allow
room for swelling. The loss of resistance in the brain leads to
transcapillary leakage due to an increase in the transcapillary
hydrostatic pressure gradient. In order to counteract this effect
of a craniectomy, the transcapillary pressure must be lowered
by preventing an increase in arterial pressure and infusing albumin and packed red blood cells (Olivecrona, et al. 2007). These
issues are all collateral damage of decompressive craniectomies,
but the benefit of the surgery seems to outweigh the detriment.
An important factor to consider is the timing of the procedure.
While most craniectomies are performed after standard protocol has been tried and found unsuccessful, thus lengthening the
amount of time between the injury and the surgery, this might
not be the most advantageous use of craniectomies. Akyuz, et al.
(2010) compared the results of craniectomies on patients who
received the surgery following standard procedure to those
who received the surgery immediately. The first group had their
craniectomies around 35.7 hours after trauma, as compared to
the second group, who underwent the procedure approximately 4 hours after trauma. It was found that early decompressive
craniectomy resulted in a 48% decrease in intracranial pressure.
The group which underwent standard protocols before receiving craniectomies yielded a 27.8% favorable outcome as compared to the other group, which had a 50% favorable outcome
after 12 months. While the best results were found when the
procedure was performed within 4 hours of injury, performing
the craniectomy within 48 hours still provides benefit (Qiu, et
al. 2009). Using craniectomy as a second tier response hinders
the positive effects of the procedure, as an extended amount of
time with high intracranial pressure is detrimental to functional
outcome.
The size of the decompressive craniectomy is also significant. If
the craniectomy is too small, it will not allow the brain enough
room to expand. The brain will then swell through the incision,
causing external herniation. Bilateral craniectomies have the advantage of providing more space for the brain to expand (Akyuz,
et al. 2010).
Age is also an integral consideration when determining the outcome of decompressive craneictomy. In fact, the study done by
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Cooper, et al. (2012), which found the least favorable results,
was the study which included the oldest patients. It seems that
the highest recommended age upon which a craniectomy for
traumatic brain injury should be performed is 40, and that it is
detrimental to those over 60 (Akyuz, et al. 2010; Morgalla, et al.
2008; Olivecrona, et al. 2007). The greatest benefit is to younger
patients. This might be due to a stronger immune system or to
an elevated recovery ability in younger patients.

Conclusion
These three responses to traumatic brain injury are still being
researched. From the studies analyzed, it is apparent that due to
the negligible benefit and immense cost of using hypertonic saline, it should be reserved for patients with injuries that indicate
surgery. The status of hypertonic saline as a first tier response
should be reevaluated. Progesterone, on the other hand, should
be initiated into standard protocol. It shows no discernable
harm and has been proven to do much good. It is essential that
it be included in first tier response, as the immediacy of administration bears effect on the amount of good it can do for
the patient. Decompressive craniectomy should be considered
immediately in a case of uncontrollable intracranial pressure in
a relatively young patient, so as to capitalize on the efficacy of a
rapid craniectomy. In such a case, the gains outweigh potential
damage. However, all assessments must be made on an individual basis, as each patient presents a unique set of properties.
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